文献速递慢阻肺

慢阻肺发病机制:在复杂中寻找共性

COPD Pathogenesis: Finding the Common in the Complex.
PubMed 文献 · Chest · 2018-08-03

该文提出肺气肿性改变可被视为一种涌现现象:分子水平改变累积至临界结构阈值后,不均匀机械力导致肺泡壁破裂,并伴随慢阻肺晚期临床征象。将涌现性形态变化与生物标志物耦合,以检测并治疗性对抗该过程,是务实的疾病应对策略。

要点

  • 肺气肿性改变或为分子改变达临界结构阈值后的涌现现象。
  • 肺泡壁破裂由不均匀机械力在结构阈值处产生。
  • 生物标志物耦合形态变化或有助于检测并治疗性干预。

核心结论

  • 肺气肿性改变可能更准确地描述为一种涌现现象,涉及分子水平改变达到临界结构阈值后由不均匀机械力导致肺泡壁破裂。

主要发现

  • 目前尚无公认模型涵盖导致肺气肿性气腔扩大的生化与力学过程。
  • 分子水平改变最终达到临界结构阈值,不均匀机械力产生肺泡壁破裂,并伴随慢阻肺晚期临床征象。

临床怎么用

  • 将涌现性形态变化与生物标志物耦合,以检测该过程并进行治疗性对抗,代表一种务实的疾病应对方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Developing an effective treatment for COPD, and especially pulmonary emphysema, will require an understanding of how fundamental changes at the molecular level affect the macroscopic structure of the lung. Currently, there is no accepted model that encompasses the biochemical and mechanical processes responsible for pulmonary airspace enlargement. We propose that pulmonary emphysematous changes may be more accurately described as an emergent phenomenon, involving alterations at the molecular level that eventually reach a critical structural threshold where uneven mechanical forces produce alveolar wall rupture, accompanied by advanced clinical signs of COPD. The coupling of emergent morphologic changes with biomarkers to detect the process, and counteract it therapeutically, represents a practical approach to the disease.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Cantor JO, Turino GM. COPD Pathogenesis: Finding the Common in the Complex. Chest. 2018. PMID: 30080996. doi:10.1016/j.chest.2018.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。